#USA #Chicago #Genprex #Reqorsa #AACR 2025

Genprex Reports Positive Advances with Reqorsa Gene Therapy

Genprex, Inc., a pioneering company in gene therapy, has announced notable preclinical results showcasing the effectiveness of its Reqorsa® gene therapy in treating non-small cell lung cancer (NSCLC) that is resistant to Ras inhibitors. The research findings were presented during the prestigious 2025 American Association for Cancer Research (AACR) Annual Meeting held in Chicago, Illinois, from April 25 to 30, 2025.

Overview of Findings

The treatment specifically targets KRASG12C mutant NSCLC cases, which have historically posed significant challenges due to their resistance to existing therapies. At the conference, Ryan Confer, the President, and CEO of Genprex, expressed enthusiasm about the results, noting that they bolster the therapeutic potential of Reqorsa both as a standalone treatment and in conjunction with existing Ras inhibitors.

Preclinical Data Highlights

The spotlight of Genprex's presentation was a poster titled "Overcoming Sotorasib Acquired Resistance in KRASG12C Mutant NSCLC by TUSC2 Gene Therapy." It underscored how Reqorsa effectively addresses the resistance developed against Sotorasib (LUMAKRAS®) in NSCLC mouse xenografts. The studies demonstrated:

• - Significant reductions in colony formation in resistant cell lines.
• - Enhanced rates of apoptosis in treated cells.
• - Notable decreases in tumor viability following treatment with the TUSC2 gene therapy.

Interestingly, the research indicated that tumors exhibiting acquired resistance to Sotorasib displayed significantly lower sensitivity to the drug alone, highlighting the need for alternative therapeutic strategies. By employing Reqorsa, however, tumor growth was controlled more effectively compared to treatment with Sotorasib alone. Furthermore, the combination of Reqorsa and Sotorasib showed a synergistic antitumor effect, paving the way for potentially more effective dual therapy approaches.

The Mechanism Behind Reqorsa

Reqorsa, featuring the TUSC2 gene, utilizes a non-viral delivery system encapsulated in lipid-based nanoparticles. This innovative approach allows for targeted delivery of the TUSC2 gene directly into cancer cells, enhancing the chances of re-establishing tumor suppressor functions that are often lost in cancer pathology. In laboratory studies at MD Anderson, TUSC2 uptake in tumor cells was significantly higher than in normal cells, suggesting a robust targeting mechanism that minimizes damage to healthy tissue.

Future Directions for Genprex

Genprex is strategically positioned to pursue further clinical trials based on these promising results, which could lead to expanded treatment options for patients. The company is concurrently advancing its gene therapy pipeline for both oncology and diabetes, aiming to address a wider array of serious health issues through groundbreaking research and development efforts.

Conclusion

The presentation at AACR 2025 marks a critical milestone for Genprex, showcasing how Reqorsa could reshape the treatment landscape for patients suffering from Ras inhibitor-resistant lung cancer. As the data continues to unfold, Genprex remains committed to exploring innovative therapeutic pathways that could enhance patient outcomes in the challenging arena of cancer treatment. Interested stakeholders can access the detailed findings on Genprex's official website.

For more information about Genprex and its treatment modalities, visit Genprex Website.